Skip to main content

Table 3 Perceptions of vaccine effectiveness and safety for B cell deficiency and CID

From: Physician vaccination practices in mild to moderate inborn errors of immunity and retrospective review of vaccine completeness in IEI: results from the Canadian Immunization Research Network

Vaccine effectiveness (N = 45)

Vaccine safety (N = 45)

 

Very/somewhat effective

Very/somewhat ineffective

Don’t know

Respondents that answered question (n)

Respondents that did not answer*

(n)

Very/somewhat safe

Very/somewhat unsafe

Don’t know

Respondents that answered question (n)

Respondents that did not answer*

(n)

B cell IEI

          

DTaP/Tdap

42% (19)

7% (3)

29% (13)

35

10

69% (31)

0% (0)

7% (3)

34

11

Influenza (IIV)

36% (16)

7% (3)

33% (15)

34

11

62% (28)

4% (2)

7% (3)

33

12

Influenza (LAIV)

22% (10)

9% (4)

44% (20)

34

11

36% (16)

22% (10)

18% (8)

34

11

MMR/Varicella/MMRV

31% (14)

11% (5)

36% (16)

35

10

38% (17)

24% (11)

13% (6)

34

11

Rotavirus

22% (10)

11% (5)

44% (20)

35

10

36% (16)

16% (7)

18% (8)

31

14

CID IEI

          

DTaP/Tdap

44% (20)

9% (4)

22% (10)

34

11

67% (30)

2% (1)

4% (2)

33

12

Influenza (IIV)

40% (18)

9% (4)

24% (11)

33

12

58% (26)

4% (2)

11% (5)

33

12

Influenza (LAIV)

13% (6)

16% (7)

44% (20)

33

12

13% (6)

40% (18)

20% (9)

35

10

MMR/Varicella/MMRV

24% (11)

18% (8)

29% (13)

32

13

16% (7)

49% (22)

9% (4)

33

12

Rotavirus

16% (7)

11% (5)

44% (20)

32

13

13% (6)

38% (17)

20% (9)

32

13

  1. Imm Immunologists, IDS Infectious Disease Specialists, MMR Measles/Mumps/Rubella Vaccine, MMRV Measles/Mumps/Rubella/Varicella Vaccine, DTaP-Hib-IPV Diptheria/Tetanus/acellular pertussis/Haemophilus Influenzae B/Inactivated Polio Vaccine, DTaP Diphtheria/Tetanus/Acellular Pertussis Vaccine, TdaP Tetanus/lower dose Diphtheria/Acellular Pertussis Vaccine, IIV Inactivated Influenza Vaccine, LAIV Live Attenuated Influenza Vaccine
  2. “Mild/moderate primary B cell defects”: Clearly defined mild to moderate primary humoral defects (e.g. IgA deficiency, IgG subclass deficiency, specific antibody deficiency, transient hypogammaglobulinemia of infancy) and other unspecified or syndrome-related mild/moderate primary hypogammaglobulinemia (e.g. Down syndrome)
  3. “Mild/moderate CID”: Characterized by an incomplete reduction in T-cell number or activity where part of the immune system’s ability to respond to infectious organisms is retained (e.g. partial DiGeorge syndrome, Ataxia Telangiectasia, Wiskott Aldrich syndrome, Early Purine Nucleoside Phosphorylase Deficiency)
  4. *For each question, participants who did not answer were excluded when calculating the proportions
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us